R&D Pipeline
Focusing on major disease areas to develop globally competitive innovative drugs
R&D Platform
Drug Discovery Platform
Structure-based drug design, high-throughput screening, lead optimization
Clinical Development
China-US dual filing experience and international clinical development team
Built a full R&D pipeline from drug molecular design to commercialization
Core Products
F-02-2-Na
Indication
Gout / Hyperuricemia
Mechanism
URAT1 Inhibitor
Stage
IND Approved
IND approved in China and the U.S. (August 2025)
Competitive Advantage
High selectivity, low toxicity, superior to current therapies
Anti-Cancer Drug
Indication
Glioma
Mechanism
Overcome drug resistance
Stage
PCC Stage
IND filing expected 2026
Competitive Advantage
Targeting drug-resistant tumors, filling a market gap
XCY-A-006-a31
Indication
Insomnia
Mechanism
Orexin Receptor (OXR)
Stage
PCC Stage
Preclinical studies in progress
Competitive Advantage
Novel mechanism, improves sleep quality